In this update, we examine Spain’s comprehensive pharmaceutical legislation reform; France’s refined health economic evaluation approach; and the US’ proposed Most Favored Nation pricing mechanism.
Ramagopalan et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: